Date: 2014-02-18
Type of information: Collaboration agreement
Compound: antibody drug conjugates (ADC)
Company: BioOutsource (UK) Glythera (UK)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On February 18, 2014, BioOutsource, an international Contract Testing Organization (CTO) has announced a partnership with Glythera Ltd, a biotechnology company based in Newcastle-upon-Tyne that specializes in the development of next generation biotherapeutics through the application of its proprietary linker and stable glycan technologies. “Building on our position as a leader in biological characterisation of monoclonal antibodies, ADC’s represent an exciting development which will enhance the performance of a wide range of therapeutic products. We are delighted to partner with Glythera to characterise their ADC product in development, as we believe it holds considerable promise,” commented BioOutsource CSO, Daniel Galbraith.
Financial terms:
Latest news:
